OCUP (Ocuphire Pharma) מכפיל P/E עתידי

לוגו גרפי של Ocuphire Pharma, Inc. (OCUP)

The current forward P/E ratio of Ocuphire Pharma, Inc. (OCUP) reflects analyst expectations, with the 0.00 value correlating with the trial process for retinal treatments in the US. The business fundamentals rely on the development of Nyxol for non-surgical vision correction. The technology stack is further enhanced by automated data analysis systems and robotic molecule screening in laboratories.

ocuphire.com - יחס מחיר לרווח חזוי OCUP (תקופה 04.07.2022 - 24.10.2024)

פילוחים אנליטיים ודוחות נתונים של חברת ocuphire.com (OCUP)

- מחיר נוכחי ושווי מניות חזוי:
ניתוח כל מדדי החברה:Ocuphire Corporation
מוצר ממותג של Ocuphire Pharma, Inc.

Analyzing Ocuphire Pharma, Inc. (OCUP) through the forward P/E multiple allows for a comparison of the company's current market value against its projected net income. This indicator assesses the long-term capitalization trend, and within the biopharmaceutical sector, it is critically sensitive to clinical trial results and the effectiveness of patent protection, which determine future profitability and the business's resilience to market downturns.